From May through November 2023, Total Health will host "Cancer Updates: A Dinner Series for Community Care Teams" at the Marriott Memphis East Hotel in Memphis, Tennessee.
The dinner series will consist of educational activities designed to meet the needs of medical oncologists, pharmacists, advanced practitioners, and nurses involved in the treatment of various cancers; including lung cancers, gastrointestinal cancers, breast cancers, genitourinary cancers, and hematological malignancies.
Each tumor-focused program agenda is comprised of multidisciplinary, case-based presentations that will break down the most clinically relevant information applicable to community care. These dinner programs will be hosted as an in-person events only.
See dinner program schedule below. Register free for one or more events.
Dinner Program Schedule
Lung Cancer Dinner Program
Tuesday, May 23, 2023
5:30 - 8:00 PM CST
In-Person Only
Marriott Memphis East Hotel, TN
CE/CME credits & MOC points
2.50
GU Cancer Dinner Program
Thursday, September 7, 2023
5:30 - 8:00 PM CST
In-Person Only
Marriott Memphis East Hotel, TN
CE/CME credits & MOC points
2.50
GI Cancer Dinner Program
Tuesday, June 13, 2023
5:30 - 8:00 PM CST
In-Person Only
Marriott Memphis East Hotel, TN
CE/CME credits & MOC points
2.50
Hematology Dinner Program
Tuesday, November 7, 2023
5:30 - 8:00 PM CST
In-Person Only
Marriott Memphis East Hotel, TN
CE/CME credits & MOC points
2.50
Breast Cancer Dinner Program
Thursday, July 27, 2023
5:30 - 8:00 PM CST
In-Person Only
Marriott Memphis East Hotel, TN
CE/CME credits & MOC points
2.50
Accreditation Information | 2.50
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 2.50 ANCC contact hours.
Physicians (ACCME) Credit Designation
Amedco LLC designates this live activity for a maximum of 2.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists and Pharmacy Technicians (ACPE) Credit Designation
Amedco LLC designates this activity for a maximum of 2.50 knowledge-based CPE contact hours.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
American Board of Internal Medicine (ABIM) MOC Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS.
Learning Objectives
-
Employ an understanding of personalized medicine to individualize the use of available drugs for lung cancers, gastrointestinal cancers, breast cancers, genitourinary cancers, and hematological malignancies.
-
Communicate the efficacy and safety of the drugs discussed in the case studies and other emerging treatments for lung cancers, gastrointestinal cancers, breast cancers, genitourinary cancers, and hematological malignancies.
-
Understand the emerging and standard diagnostic tests used to assist in planning therapy for lung cancers, gastrointestinal cancers, breast cancers, genitourinary cancers, and hematological malignancies.
-
Formulate management strategies, considering the contributory roles of local and systemic therapy.
-
Recall the design of ongoing clinical trials evaluating novel investigational agents and counsel appropriately selected patients about availability and participation.